Patent intelligence · WO
WO 2018227427
DÉRIVÉS DE DIAZÉPANE PONTÉS SUBSTITUÉS ET LEUR UTILISATION
DÉRIVÉS DE DIAZÉPANE PONTÉS SUBSTITUÉS ET LEUR UTILISATION
Patent details — WO 2018227427
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Dec 20, 2018
- Expiration
- Dec 15, 2038
- Applicant
- BAYER AG [DE]
- CPC classes
- A61K/315513, A61K/4506, A61P/1100, A61P/2500
Quick answer
WO 2018227427 (DÉRIVÉS DE DIAZÉPANE PONTÉS SUBSTITUÉS ET LEUR UTILISATION) is held by BAYER AG [DE]. Status: granted. Granted Dec 20, 2018. Expires Dec 15, 2038 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/315513, A61K/4506, A61P/1100, A61P/2500
More from BAYER AG [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 2018227427?
WO 2018227427 (DÉRIVÉS DE DIAZÉPANE PONTÉS SUBSTITUÉS ET LEUR UTILISATION) is held by BAYER AG [DE]. Status: granted. Granted Dec 20, 2018. Expires Dec 15, 2038 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2018227427?
BAYER AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does WO 2018227427 expire?
Our index shows an expiration date of Dec 15, 2038 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.